Lille

• BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma Ended
  2024-518931-12-00 4 2014-05-15 Neuroblastoma
• A Phase 1 study to evaluate IK-930 in subjects with advanced solid tumors Ended
  2022-502622-40-00 1 Advanced Solid Tumors
• C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People … Ended
  2022-502822-41-00 9 Relapsed/Refractory Diffuse Large B Cell Lymphoma
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan … Ended
  2023-506487-13-00 5 Hormone receptor-positive, her2-negative advanced/metastatic breast ca
• A trial to find out if vidutolimod together with cemiplimab is safe and if it works in adult participants with advanced cancer or metastatic … Ended
  2023-507344-36-01 4 Advanced or Metastatic Cancer Merkel Cell Carcinoma (MCC) Cutaneous Sq
• MK-1200 for Advanced Solid Tumors Ended
  2023-508684-68-00 9 Advanced solid tumor
• ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in pati … Ended
  2023-509227-41-00 4 Low risk of disease recurrence, defined by the following criteria: - A
• An open label phase II basket trial exploring the efficacy and safety of the combination of Niraparib and Dostarlimab in patients with DNA r … Ended
  2024-514855-13-00 4 DNA repair-deficient or platinum-sensitive solid tumors
• Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanc … Ended
  2024-515533-15-00 4 Locally advanced cervical cancer
• Trail aiming to assess the safety and clinical activity of bemarituzumab + bevacizumab in advanced/metastatic gynecological cancer overexpre … Ended
  2024-516724-33-00 9 Advanced/metastatic gynecological cancer overexpressing FGFR2b
• DCC-3084 monotherapy in patients with solid tumors Ended
  2024-517829-12-00 7 Solid tumors driven by the MAPK Pathway
• PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) … Ended
  2024-519258-35-00 4 stomach cancer
• A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced melanoma Ended
  2025-522054-40-00 4 Previously treated advanced melanoma
• A multicentric phase II trial evaluating volrusotmig in patients with mature tertiary lymphoid structures solid tumors. Expired
  2023-503451-94-00 4 Adult participants with metastatic (advanced) solid tumors

Showing 673–686 of 686 trials